Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

01.11.2021

1 Acta Neurol Scand
1 Ann N Y Acad Sci
1 Ann Neurol
1 Arch Phys Med Rehabil
3 BMC Neurol
1 J Neuroimmunol
2 J Neurol
1 J Neurol Neurosurg Psychiatry
2 J Neurol Sci
4 Lancet Neurol
9 Mult Scler
1 Neurologia (Engl Ed)
4 Neurology
1 PLoS One
1 Rev Neurol



    Acta Neurol Scand

  1. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on common multiple sclerosis symptoms.
    Acta Neurol Scand. 2021 Oct 22. doi: 10.1111/ane.13540.
    >> Share


    Ann N Y Acad Sci

  2. VELDKAMP R, Moumdjian L, van Dun K, Six J, et al
    Motor sequence learning in a goal-directed stepping task in persons with multiple sclerosis: a pilot study.
    Ann N Y Acad Sci. 2021 Oct 24. doi: 10.1111/nyas.14702.
    >> Share


    Ann Neurol

  3. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    >> Share


    Arch Phys Med Rehabil

  4. GROMISCH ES, Turner AP, Leipertz SL, Beauvais J, et al
    Demographic and clinical factors are associated with frequent short-notice cancellations in Veterans with multiple sclerosis on disease modifying therapies.
    Arch Phys Med Rehabil. 2021 Oct 22. pii: S0003-9993(21)01499.
    >> Share


    BMC Neurol

  5. OH J, Arbour N, Giuliani F, Guenette M, et al
    The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design.
    BMC Neurol. 2021;21:418.
    >> Share

  6. DEHGHANI A
    Development and validation of the disease - specific problems questionnaire for patients with multiple sclerosis.
    BMC Neurol. 2021;21:415.
    >> Share

  7. OWLIA F, Mahmoudzade N, Modaresi J, Zarchi MA, et al
    Evaluation of the response to electric pulp testing in multiple sclerosis patients without a history of trigeminal neuralgia: a case-control study.
    BMC Neurol. 2021;21:403.
    >> Share


    J Neuroimmunol

  8. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    >> Share


    J Neurol

  9. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    >> Share

  10. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    >> Share


    J Neurol Neurosurg Psychiatry

  11. KONIG M, Lorentzen AR, Torgauten HM, Tran TT, et al
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
    J Neurol Neurosurg Psychiatry. 2021 Oct 20. pii: jnnp-2021-327612.
    >> Share


    J Neurol Sci

  12. SCOTT TF
    Neurosarcoidosis mimicry of MS: Clues from cases with CNS tissue diagnosis.
    J Neurol Sci. 2021;429:117621.
    >> Share

  13. BEARD K, Sriwastava S
    Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis.
    J Neurol Sci. 2021;430:120034.
    >> Share


    Lancet Neurol

  14. HOHLFELD R
    Mesenchymal stem cells for multiple sclerosis: hype or hope?
    Lancet Neurol. 2021;20:881-882.
    >> Share

  15. HOHLFELD R
    Multiple sclerosis meets systems immunology.
    Lancet Neurol. 2021;20:887-888.
    >> Share

  16. BAR-OR A, Li R
    Multiple sclerosis meets systems immunology - Authors' reply.
    Lancet Neurol. 2021;20:888.
    >> Share

  17. UCCELLI A, Laroni A, Ali R, Battaglia MA, et al
    Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Lancet Neurol. 2021;20:917-929.
    >> Share


    Mult Scler

  18. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    >> Share

  19. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    >> Share

  20. SAHRAIAN MA
    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
    >> Share

  21. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
    >> Share

  22. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
    >> Share

  23. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    >> Share

  24. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    >> Share

  25. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    >> Share

  26. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    >> Share


    Neurologia (Engl Ed)

  27. PATO PATO A, Costa Arpin E, Rodriguez Regal A, Rodriguez Constenla I, et al
    Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.
    Neurologia (Engl Ed). 2021;36:346-352.
    >> Share


    Neurology

  28. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    >> Share

  29. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    >> Share

  30. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    >> Share

  31. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    >> Share


    PLoS One

  32. ROZYCKA J
    How I see is how I feel. Identification of illness perception schema and its association with adaptation outcomes in multiple sclerosis - a 5-year prospective study.
    PLoS One. 2021;16:e0258740.
    >> Share


    Rev Neurol

  33. ZABAY-NEIRO MC, Nieves-Collado M, Carres-Gonzalez G, Curto-Estupina G, et al
    [Evaluation of the impact of lockdown on the health and lifestyle of users of the Fundacio Esclerosi Multiple's neurorehabilitation centres in Lleida and Reus].
    Rev Neurol. 2021;73:249-257.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016